Pharma.Aero has elected Trevor Caswell as its new chairman, presiding over its board of directors for the next two years.

The non-profit organisation was founded in 2016 to foster collaboration between pharma manufacturers and air cargo stakeholders from around the world.

Caswell is manager, demand & product development (cargo) at Edmonton International Airport – a strategic member of Pharma.Aero since 2019.

The board of directors consists of five positions filled by representatives of five Pharma.Aero strategic airport members. The five members elected after the 2022 general assembly at the end of March are: Trevor Caswell (Edmonton International Airport) – chair; Jeremy Mitchell (Sharjah Airport Authority) – vice-chair; Jaisey Yip (Changi Airport Group/representing Lim Ching Kiat) – vice-chair; Bruno Guela (managing director, Latin America Cargo City) – treasurer; and Nathan De Valck (Brussels Airport Company) – past-chair.

Caswell takes over from Nathan De Valck, who presided over the board of directors since its creation, in 2019.

Caswell commented: “Edmonton International Airport has been an active strategic member of Pharma.Aero since early 2019 [and] strongly supports the role that Pharma.Aero plays in the global pharmaceutical supply chain.

“I have thoroughly enjoyed my role as vice-chairman with the board of directors, focused on the project management and development around new project ideas that have expanded our organisational project scope.

“I am thrilled and honoured to begin my new role as chairman, following the tremendous work that Nathan De Valck has successfully led over the past six years.  I would like to thank him for all of his time and dedication.

“Over the next two years, I look forward to working with the rest of our dedicated team – our back-office, board of directors and our advisory board, in order to continue building a strong organisation for our members.

“While Pharma.Aero continues to grow, we will ensure that we remain the essential link that connects pharma shippers with all the strategic partners in the pharmaceutical supply chain. We will ensure we remain the leading cross-industry organisation, by continuing to collaborate and coordinate projects that address real challenges in the global pharma supply chain.”